Continuous background correction of refractive index signal to improve monoclonal antibody concentration monitoring during UF/DF and SPTFF operations

2022 ◽  
Author(s):  
Thaddaeus A. Webster ◽  
Kelley Turner ◽  
Caitlin DuBois ◽  
Ryan MacDougall ◽  
Carrie Mason
Keyword(s):  
Monoclonal Antibody ◽  
Refractive Index ◽  
Background Correction ◽  
Antibody Concentration ◽  
Continuous Background

scholarly journals Development and evaluation of a monoclonal antibody-based competitive ELISA for the detection of antibodies against H7 avian influenza virus

2021 ◽  
Vol 17 (1) ◽  
Author(s):  
Yuan Li ◽  
Hongliu Ye ◽  
Meng Liu ◽  
Suquan Song ◽  
Jin Chen ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Influenza Virus ◽  
Avian Influenza ◽  
Avian Influenza Virus ◽  
Large Scale ◽  
Operation Time ◽  
Reference Method ◽  
Antibody Detection ◽  
Enzyme Linked Immunosorbent Assay ◽  
Antibody Concentration

Abstract Background H7 subtype avian influenza has caused great concern in the global poultry industry and public health. The conventional serological subtype-specific diagnostics is implemented by hemagglutination inhibition (HI) assay despite lengthy operation time. In this study, an efficient, rapid and high-throughput competitive enzyme-linked immunosorbent assay (cELISA) was developed for detection of antibodies against H7 avian influenza virus (AIV) based on a novel monoclonal antibody specific to the hemagglutinin (HA) protein of H7 AIV. Results The reaction parameters including antigen coating concentration, monoclonal antibody concentration and serum dilution ratio were optimized for H7 antibody detection. The specificity of the cELISA was tested using antisera against H1 ~ H9, H11 ~ H14 AIVs and other avian viruses. The selected cut-off values of inhibition rates for chicken, duck and peacock sera were 30.11, 26.85 and 45.66% by receiver-operating characteristic (ROC) curve analysis, respectively. With HI test as the reference method, the minimum detection limits for chicken, duck and peacock positive serum reached 20, 21 and 2− 1 HI titer, respectively. Compared to HI test, the diagnostic accuracy reached 100, 98.6, and 99.3% for chicken, duck and peacock by testing a total of 400 clinical serum samples, respectively. Conclusions In summary, the cELISA assay developed in this study provided a reliable, specific, sensitive and species-independent serological technique for rapid detection of H7 antibody, which was applicable for large-scale serological surveillance and vaccination efficacy evaluation programs.

Therapeutic monoclonal antibody concentration monitoring: free or total?

Bioanalysis ◽  
2010 ◽  
Vol 2 (6) ◽  
pp. 1125-1140 ◽  
Author(s):  
Bing Kuang ◽  
Lindsay King ◽  
Huifen Faye Wang
Keyword(s):  
Monoclonal Antibody ◽  
Antibody Concentration ◽  
Therapeutic Monoclonal Antibody

scholarly journals Development and evaluation of a monoclonal antibody-based competitive ELISA for the detection of antibodies against H7 avian influenza virus

2020 ◽  
Author(s):  
Yuan Li ◽  
Hongliu Ye ◽  
Meng Liu ◽  
Suquan Song ◽  
Jin Chen ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Influenza Virus ◽  
Avian Influenza ◽  
Avian Influenza Virus ◽  
Large Scale ◽  
Operation Time ◽  
Reference Method ◽  
Antibody Detection ◽  
Enzyme Linked Immunosorbent Assay ◽  
Antibody Concentration

Abstract Background: H7 subtype avian influenza have caused great concern in the global poultry industry and public health. The conventional serological subtype-specific diagnostics is implemented by hemagglutination inhibition (HI) assay despite lengthy operation time. In this study, an efficient, rapid and high-throughput competitive enzyme-linked immunosorbent assay (cELISA) was developed for detection of antibodies against H7 avian influenza virus (AIV) based on a novel monoclonal antibody specific to the hemagglutinin (HA) protein of H7 AIV. Results: The reaction parameters including antigen coating concentration, monoclonal antibody concentration and serum dilution ratio were optimized for H7 antibody detection. The specificity of the cELISA was tested using antisera against H1~H9, H11~H14 AIVs and other avian viruses. The selected cut-off values of inhibition rates for chicken, duck and peacock sera were 30.11%, 26.85% and 45.66% by receiver-operating characteristic (ROC) curve analysis, respectively. With HI test as the reference method, the minimum detection limits for chicken, duck and peacock positive serum reached 2 0 , 2 1 and 2 -1 HI titer, respectively. Compared to HI test, the diagnostic accuracy reached 100%, 98.6%, and 99.3% for chicken, duck and peacock by testing a total of 400 clinical serum samples, respectively. Conclusions: In summary, the cELISA assay developed in this study provided a reliable, specific, sensitive and species-independent serological technique for rapid detection of H7 antibody, which was applicable for large-scale serological surveillance and vaccination efficacy evaluation programs.

Static Fourier transform mid-infrared spectrometer with continuous background correction

2019 ◽  
Author(s):  
Michael H. Köhler ◽  
Michael Schardt ◽  
Hamza B. Ghazala ◽  
Ennio Colicchia ◽  
Patrick Kienle ◽  
...  
Keyword(s):  
Fourier Transform ◽  
Background Correction ◽  
Mid Infrared ◽  
Continuous Background ◽  
Infrared Spectrometer

scholarly journals Development and evaluation of a monoclonal antibody-based competitive ELISA for the detection of antibodies against H7 avian influenza virus

2020 ◽  
Author(s):  
Yuan Li ◽  
Hongliu Ye ◽  
Meng Liu ◽  
Suquan Song ◽  
Jin Chen ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Influenza Virus ◽  
Avian Influenza ◽  
Avian Influenza Virus ◽  
Large Scale ◽  
Operation Time ◽  
Reference Method ◽  
Enzyme Linked Immunosorbent Assay ◽  
Antibody Concentration ◽  
Roc Curve Analysis

Abstract Background Since 2013, avian influenza outbreaks in poultry especially the H7 subtype have been causing a major concern for poultry industry and public health in China. The conventional serological subtype-specific diagnostics is implemented by hemagglutination inhibition (HI) assay despite lengthy operation time. An efficient, rapid and high-throughput competitive enzyme-linked immunosorbent assay (cELISA) was developed for detection of antibodies against H7 avian influenza virus (AIV) based on a novel monoclonal antibody specific to the hemagglutinin (HA) protein of H7 AIV. Results The reaction parameters of antigen coating concentration, monoclonal antibody concentration and serum dilution ratio were optimized for detection of H7 antibodies in chicken, ducks and peacocks sera. The specificity of the cELISA was tested using antisera against H1 ~ H9, H11 ~ H14 AIVs and other avian viruses. The selected cut-off values of inhibition rates for chicken, duck and peacock sera were 30.11%, 26.85% and 45.66% by receiver-operating characteristic (ROC) curve analysis, respectively. With the HI test as a reference method, the minimum detection limits for chicken, duck and peacock positive serum reached 20, 21 and 2− 1 HI titer, respectively. Compared to the HI test, the diagnostic accuracy reached 100%, 98.6%, and 99.3% for chicken, duck and peacock by testing a total of 400 clinical serum samples, respectively. Conclusions In summary, the cELISA immunoassay for rapid detection of H7 antibody in sera from different avian species was highly specific, extremely sensitive and might be exploited for the large-scale serological diagnosis of H7 AIVs.

Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of Rituximab

1999 ◽  
Vol 17 (6) ◽  
pp. 1851-1851 ◽  
Author(s):  
T. A. Davis ◽  
C. A. White ◽  
A. J. Grillo-López ◽  
W. S. Velásquez ◽  
B. Link ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Phase Ii ◽  
Hodgkin’S Lymphoma ◽  
Phase Ii Trial ◽  
Single Agent ◽  
Lesion Size ◽  
Hodgkin's Lymphoma ◽  
Antibody Concentration ◽  
Low Grade ◽  
Non Hodgkin's Lymphoma

PURPOSE: A phase II trial was performed to evaluate the safety and efficacy of rituximab, a chimeric anti-CD20 monoclonal antibody, in patients with bulky (> 10-cm lesion) relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma (NHL). PATIENTS AND METHODS: Thirty-one patients received intravenous infusions of rituximab 375 mg/m2 weekly for four doses. All patients had at least one prior therapy (median, three; range, one to 13) and had progressive disease at study entry. Patients were a median of 4 years from diagnosis. RESULTS: No patient had treatment discontinued because of an adverse event. No patient developed human antichimeric antibody. The overall response rate in 28 assessable patients was 43% with a median time to progression of 8.1 months (range, 4.5 to 18.6+ months) and median duration of response of 5.9 months (range, 2.8 to 12.1+ months). The average decrease in lesion size in patients who achieved a partial response was 76%, and patients with stable disease had a decrease in average lesion size of 26%. Median serum antibody concentration was higher in responders compared with nonresponders, and a negative correlation was shown between antibody concentration and tumor bulk at baseline. CONCLUSION: Rituximab single-agent outpatient therapy is safe and shows significant clinical activity in patients with bulky relapsed or refractory low-grade or follicular B-cell NHL.

Quantification of lactate dehydrogenase-1 in serum with use of an M-subunit-specific monoclonal antibody.

1988 ◽  
Vol 34 (12) ◽  
pp. 2410-2414 ◽  
Author(s):  
H C Vaidya ◽  
S E Porter ◽  
Y Landt ◽  
D P Silva ◽  
D N Dietzler ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Lactate Dehydrogenase ◽  
Antibody Concentration ◽  
Specific Monoclonal Antibody ◽  
Diagnostic Systems ◽  
High Concentration ◽  
Electrophoretic Method ◽  
Latex Particles ◽  
One Step ◽  
Micron Diameter

Abstract We have developed a rapid, one-step assay for measuring lactate dehydrogenase-1 (LD-1) activity in serum after extraction of LD-2, LD-3, LD-4, and LD-5 isoenzymes by an immobilized M-subunit-specific monoclonal antibody (D.8.1). In the assay, 100 microL of serum is mixed with 50 microL of a suspension of 0.8-micron-diameter latex particles coated with 30 micrograms of the monoclonal antibody D.8.1, then incubated at room temperature for 5 min. The latex particles, to which LD-2 through LD-5 are bound, are pelleted by centrifugation for 2 min at 12,000 X g, and the LD-1 activity is measured kinetically in the supernatant fluid. We optimized the assay for antibody immobilization, antibody concentration, and time and temperature of incubation. Serum bilirubin concentrations up to 0.33 g/L (0.56 mmol/L) did not interfere in the assay. Hemolysis interfered solely through LD-1 released from erythrocytes. The within-assay CV for low-concentration quality-control material (LD-1 33 U/L) was 3.5% (n = 9) and for high-concentration material (LD-1 185 U/L) was 1.9% (n = 8); the between-assay CVs for the two materials were 6.1% (n = 9) and 2.5% (n = 10), respectively. The LD-1 activity measured in 98 samples by our assay compared well with a two-step polyclonal antibody-based assay (Isomune-LD, Roche Diagnostic Systems; r = 0.998) and with an electrophoretic method (Paragon, Beckman Instruments; r = 0.956).

A High Speed Method of Continuous Background Correction in Atomic Absorption Spectrometry

1975 ◽  
Vol 29 (2) ◽  
pp. 149-153 ◽  
Author(s):  
T. H. Donnelly ◽  
A. J. Eccleston ◽  
R. L. Gully
Keyword(s):  
Atomic Absorption Spectrometry ◽  
Atomic Absorption ◽  
High Speed ◽  
Pulse Generator ◽  
Absorption Spectrometry ◽  
Background Correction ◽  
Light Sources ◽  
Electronic Circuitry ◽  
Continuous Background ◽  
Speed Method

Background correction in atomic absorption spectrometry using high speed electronic circuitry has been developed. Electrical responses are generated from two light sources: an atomic spectral lamp and a modified Beckman hydrogen arc lamp. Repetition rate of the pulses (2.6 msec) was limited by the increasing distortion of the pulse shape. Instantaneous relationships between the various electronic components was established using a synchronizing pulse generator.

Sign in / Sign up

Export Citation Format

Share Document